Procedural Pharmaceutical Lessons From Early Adopters
Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.
Clinical Scorecard: Procedural Pharmaceutical Lessons From Early Adopters
At a Glance
Category Detail
Condition Glaucoma Management Key Mechanisms Sustained drug delivery systems for intraocular pressure (IOP) control. Target Population Patients with open-angle glaucoma seeking alternatives to daily topical therapy. Care Setting Clinical practice integrating sustained-release pharmaceuticals.
Key Highlights
Two FDA-approved sustained-release options: Durysta and iDose TR. Patient-centered discussions are crucial for treatment selection. Sustained drug delivery can reduce the burden of daily medication. Combining procedural pharmaceuticals with other therapies can enhance IOP control. Patient selection is key for successful outcomes. Guideline-Based Recommendations
Diagnosis
Assess IOP and glaucoma severity to determine treatment options. Management
Consider sustained drug delivery as an alternative or adjunct to topical medications. Monitoring & Follow-up
Regular follow-up to evaluate IOP control and adjust treatment as necessary. Risks
Potential for ocular surface irritation and cost-related barriers to medication adherence. Patient & Prescribing Data
Patients controlled on a single glaucoma medication seeking to reduce or eliminate drops.
Patients often prefer sustained drug delivery options to avoid the challenges of daily medication.
Clinical Best Practices
Frame discussions around the benefits of sustained drug delivery for IOP control. Individualize treatment plans based on patient preferences and clinical needs. Utilize gonioscopy to assess suitability for procedures. Related Resources & Content
